Healthcare provider profile · identity verified

Jackson A Okoya, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · IRVINGTON, NJ · NPI 1174615165

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jackson A Okoya, MD received $131.14 in general payments during 2025 across 7 reported records.

Paratek Pharmaceuticals, Inc. accounted for 53.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$131.14

7 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Paratek Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$69.93	53.3%	4	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$44.33	33.8%	2	2025
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$16.88	12.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$131.14	7

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
NUZYRA Normalized: nuzyra	Drug	Paratek Pharmaceuticals, Inc.	$69.93	4	2025
Source payment records 2025-02-07 · Paratek Pharmaceuticals, Inc. · $16.79 · Open Payments source 2025-04-04 · Paratek Pharmaceuticals, Inc. · $17.30 · Open Payments source 2025-05-05 · Paratek Pharmaceuticals, Inc. · $16.86 · Open Payments source 2025-12-01 · Paratek Pharmaceuticals, Inc. · $18.98 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$44.33	2	2025
Source payment records 2025-09-12 · Novo Nordisk Inc · $20.87 · Open Payments source 2025-11-07 · Novo Nordisk Inc · $23.46 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Gilead Sciences, Inc. Exact reporting entity; no affiliate inference	2025	Biktarvy open payments reported associated product	CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766	Biktarvy · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	730	203
Atorvastatin Calcium	Atorvastatin Calcium	720	160
Pantoprazole Sodium	Pantoprazole Sodium	482	108
Eliquis	Apixaban	450	62
Albuterol Sulfate Hfa	Albuterol Sulfate	394	102
Prednisone	Prednisone	331	139
Gabapentin	Gabapentin	302	55
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	290	47
Clopidogrel	Clopidogrel Bisulfate	269	51
Metformin Hcl	Metformin Hcl	259	65
Metoprolol Succinate	Metoprolol Succinate	244	67
Losartan Potassium	Losartan Potassium	237	59
Metoprolol Tartrate	Metoprolol Tartrate	225	45
Furosemide	Furosemide	219	67
Omeprazole	Omeprazole	207	58
Montelukast Sodium	Montelukast Sodium	204	53
Carvedilol	Carvedilol	184	49
Fluticasone Propionate	Fluticasone Propionate	184	74
Diclofenac Sodium	Diclofenac Sodium	176	61
Levofloxacin	Levofloxacin	167	99
Hydralazine Hcl	Hydralazine Hcl	157	37
Levetiracetam	Levetiracetam	155	28
Promethazine Hcl	Promethazine Hcl	149	77
Zolpidem Tartrate	Zolpidem Tartrate	139	28
Tamsulosin Hcl	Tamsulosin Hcl	129	27
Ibuprofen	Ibuprofen	127	45
Lisinopril	Lisinopril	127	30
Midodrine Hcl	Midodrine Hcl	127	24
Simvastatin	Simvastatin	127	34
Milrinone In 5% Dextrose	Milrinone Lactate/D5w	118	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	115	37
Latanoprost	Latanoprost	114	19
Alprazolam	Alprazolam	109	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	109	36
Famotidine	Famotidine	108	30
Divalproex Sodium	Divalproex Sodium	106	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	100	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	98	29
Levothyroxine Sodium	Levothyroxine Sodium	95	24
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	90	26
Potassium Chloride	Potassium Chloride	81	17
Entresto	Sacubitril/Valsartan	79	11
Trazodone Hcl	Trazodone Hcl	79	11
Amoxicillin	Amoxicillin	78	55
Fluocinonide	Fluocinonide	74	20
Hydrochlorothiazide	Hydrochlorothiazide	72	18
Naproxen	Naproxen	72	34
Enoxaparin Sodium	Enoxaparin Sodium	70	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	70	20
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	70	20
Azithromycin	Azithromycin	69	48
Donepezil Hcl	Donepezil Hcl	69	12
Torsemide	Torsemide	69	23
Meloxicam	Meloxicam	68	22
Acetylcysteine	Acetylcysteine	66	suppressed
Nateglinide	Nateglinide	66	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	64	18
Amiodarone Hcl	Amiodarone Hcl	63	suppressed
Xarelto	Rivaroxaban	63	suppressed
Lactulose	Lactulose	61	23
Nifedipine Er	Nifedipine	61	16
Breo Ellipta	Fluticasone/Vilanterol	59	16
Tramadol Hcl	Tramadol Hcl	57	16
Doxycycline Hyclate	Doxycycline Hyclate	56	36
Methimazole	Methimazole	56	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	54	18
Mirtazapine	Mirtazapine	53	suppressed
Budesonide	Budesonide	52	11
Buspirone Hcl	Buspirone Hcl	52	suppressed
Insulin Lispro	Insulin Lispro	50	18
Labetalol Hcl	Labetalol Hcl	49	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	47	11
Quetiapine Fumarate	Quetiapine Fumarate	45	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	44	11
Clonidine Hcl	Clonidine Hcl	44	suppressed
Sertraline Hcl	Sertraline Hcl	44	11
Glimepiride	Glimepiride	43	15
Januvia	Sitagliptin Phosphate	42	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	41	14
Spironolactone	Spironolactone	41	11
Celecoxib	Celecoxib	40	13
Sevelamer Carbonate	Sevelamer Carbonate	38	11
Brilinta	Ticagrelor	37	suppressed
Tizanidine Hcl	Tizanidine Hcl	37	suppressed
Allopurinol	Allopurinol	36	11
Insulin Lispro Kwikpen U-100	Insulin Lispro	36	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	11
Rosuvastatin Calcium	Rosuvastatin Calcium	35	13
Chlorhexidine Gluconate	Chlorhexidine Gluconate	34	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	34	16
Timolol Maleate	Timolol Maleate	34	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Pregabalin	Pregabalin	33	suppressed
Scopolamine	Scopolamine	33	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	33	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	33	11
Lorazepam	Lorazepam	32	suppressed
Ammonium Lactate	Ammonium Lactate	30	17
Memantine Hcl	Memantine Hcl	30	suppressed
Albuterol Sulfate	Albuterol Sulfate	29	13
Brimonidine Tartrate	Brimonidine Tartrate	29	suppressed
Cefuroxime	Cefuroxime Axetil	29	23
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	29	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	24
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	28	suppressed
Fluconazole	Fluconazole	28	16
Lansoprazole	Lansoprazole	28	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	25
Retacrit	Epoetin Alfa-Epbx	28	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	27	suppressed
Hydrocortisone	Hydrocortisone	27	12
Minoxidil	Minoxidil	27	suppressed
Sodium Chloride	0.9 % Sodium Chloride	27	12
Symbicort	Budesonide/Formoterol Fumarate	27	suppressed
Glycopyrrolate	Glycopyrrolate	26	suppressed
Jardiance	Empagliflozin	26	suppressed
Risperidone	Risperidone	26	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Digoxin	Digoxin	23	suppressed
Finasteride	Finasteride	23	suppressed
Glipizide	Glipizide	23	11
Levemir Flexpen	Insulin Detemir	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	23	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Folic Acid	Folic Acid	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Nystatin	Nystatin	22	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	15
Clonazepam	Clonazepam	21	suppressed
Linzess	Linaclotide	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Ozempic	Semaglutide	21	suppressed
Bupropion Hcl	Bupropion Hcl	20	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	20	suppressed
Mupirocin	Mupirocin Calcium	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Daptomycin	Daptomycin	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Heparin Sodium	Heparin Sodium,porcine	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Atenolol	Atenolol	18	suppressed
Diltiazem Hcl	Diltiazem Hcl	18	suppressed
Nifedipine	Nifedipine	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	11
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	17	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	17	suppressed
Valsartan	Valsartan	17	suppressed
Vascepa	Icosapent Ethyl	17	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Butalbital-Acetaminophen	Butalbital/Acetaminophen	16	suppressed
Carbamazepine	Carbamazepine	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	13
Nilutamide	Nilutamide	16	suppressed
Phenytoin	Phenytoin	16	suppressed
Sps	Sodium Polystyrene Sulfon/Sorb	16	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Ssd	Silver Sulfadiazine	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Cephalexin	Cephalexin	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	14	suppressed
Riluzole	Riluzole	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Azathioprine	Azathioprine	13	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Letrozole	Letrozole	13	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	13	suppressed
Pentoxifylline	Pentoxifylline	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Silodosin	Silodosin	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	12	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	12	suppressed
Butorphanol Tartrate	Butorphanol Tartrate	12	suppressed
Clonidine	Clonidine	12	suppressed
Colchicine	Colchicine	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Halobetasol Propionate	Halobetasol Propionate	12	suppressed
Naproxen-Esomeprazole Mag	Naproxen/Esomeprazole Mag	12	suppressed
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	12	suppressed
Procrit	Epoetin Alfa	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Cefepime Hcl	Cefepime Hcl	11	suppressed
Dexlansoprazole Dr	Dexlansoprazole	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Meropenem	Meropenem	11	suppressed
Ramipril	Ramipril	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$131.14 · 7 records	Paratek Pharmaceuticals, Inc.	NUZYRA, Ozempic	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error